CymaBay Therapeutics shares jumped nearly 25% and hit a new record high in early trading after the clinical-stage biopharmaceutical company agreed to be acquired by Gilead Sciences for $4.3 billion.
Trending
- Onderkoeling kan levensgevaarlijk zijn: hier moet je op letten
- Staffordshire cancer patient welcomes newly-approved treatment
- Bank of England warns of heightened risks but trims banks’ reserve requirements | Money News
- Applications open for help from Staffordshire warm homes scheme
- Virus has killed almost 9 million birds ― and counting – DW – 12/01/2025
- Weight loss jabs conditionally backed to tackle obesity by World Health Organization | Science, Climate & Tech News
- Valentino criticised over ‘disturbing’ AI handbag ads
- Who will host? – DW – 12/01/2025
